Evotec SE (EVO) stock
EVONasdaqPharmaceutical PreparationsFiscal year ends December 31Also trades as EVOTF
$1.66−0.03 (-1.78%)
Close on Nov 12, 2026Market cap $590.23MP/E –Yield –
Evotec EPS
Diluted earnings per share is net income divided by the share count including options and convertible securities.
For fiscal 2025 it was -0.58 EUR. The highest annual figure on record is 1.30 EUR in fiscal 2021.
Annual eps
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -0.58 EUR | – |
| FY2024 | Dec 31, 2024 | -1.11 EUR | – |
| FY2023 | Dec 31, 2023 | -0.47 EUR | – |
| FY2022 | Dec 31, 2022 | -0.99 EUR | -176.2% |
| FY2021 | Dec 31, 2021 | 1.30 EUR | +3150.0% |
| FY2020 | Dec 31, 2020 | 0.04 EUR | -84.0% |
| FY2019 | Dec 31, 2019 | 0.25 EUR | – |
- Revenue
- Gross Profit
- Operating Income
- Net Income
- EBITDA
- Free Cash Flow
- Operating Cash Flow
- R&D Expenses
- Gross Margin
- Operating Margin
- Profit Margin
- Total Debt
- Cash
- Total Assets
- Shares Outstanding
- Market Cap
- Enterprise Value
- PE Ratio
- Price to Sales Ratio
- Price to Book Ratio
- EV/EBITDA
- Price to Free Cash Flow
- All statistics
See a number that looks wrong?